Hai-Hong Ran, Ran Zhang, Xue-Chun Lu, Bo Yang, Hui Fan, Hong-Li Zhu. Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review[J]. Journal of Geriatric Cardiology, 2012, 9(4): 411-414. DOI: 10.3724/SP.J.1263.2012.05251
Citation: Hai-Hong Ran, Ran Zhang, Xue-Chun Lu, Bo Yang, Hui Fan, Hong-Li Zhu. Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review[J]. Journal of Geriatric Cardiology, 2012, 9(4): 411-414. DOI: 10.3724/SP.J.1263.2012.05251

Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review

  • Because it is safe and well tolerated, imatinib is a standard first-line therapy for chronic myeloid leukemia (CML). Although there have been sporadic reports of imatinib-induced cardiotoxicity, including left ventricle (LV) dysfunction and heart failure, the evidence for it is contradictory. Here, we reported a case of an 88-year-old male patient with CML developed decompensated heart failure following imatinib therapy. Four days after the initiation of imatinib, the patient developed orthopnea, edema and a pleural effusion accompanied by abdominal distension, nausea and vomiting. The chest X-ray film showed an enlarged cardiac profile. The echocardiogram demonstrated a decreased LV ejection fraction and enlarged left-side cardiac chambers. B-type natriuretic peptide concentrations were markedly increased. The patient recovered soon after the withdrawal of imatinib and introduction of comprehensive therapy for heart failure. Imatinib-induced cardiotoxicity in elderly patients is a potentially serious complication that merits further evaluation.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return